Back to News
Market Impact: 0.2
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
Source: Newswire
Healthcare & BiotechTechnology & InnovationProduct Launches
A partnership will combine the ReBalU Protocol, Vivos’s sleep platform and a new test for cells primed for chronic disease, with potential reach to nearly 500,000 chronic-disease patients. The headline provides no financial terms, trial results or evidence of commercial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
VVOS0.55
More News
- ‘I don’t care how it’s done’: Trump pressures Ukraine to cut peace deal
- Super Micro’s stock soars after surprise update — with Dell and HPE shares joining the rally
- Australian AI data centre operator NextDC shares shed 44% on revenue delay
- SpaceX posts first operating profit as public company as AI revenue nearly triples to $7.6 billion—cruising past Starlink
- SpaceX says big AI growth fueled revenue jump
- A top medical technology stock is trading at a big discount. Here's why I'm buying